Evidence map›Paper›PMID 38597118›Full record

ArticleCancer medicine2024

Real-world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B-cell lymphoma by line of therapy.

Helmneh M Sineshaw, Christina M Zettler, Jennifer Prescott, Mahek Garg, Samhita Chakraborty, Eric M Sarpong, Claire Bai, Andrew J Belli, Laura L Fernandes, Ching-Kun Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Helmneh M SineshawMerck & Co., Inc., Rahway, New Jersey, USA.ORCID 0000-0001-6926-7895
Christina M ZettlerCOTA, Inc., New York, New York, USA.ORCID 0000-0002-7516-593X
Jennifer PrescottMerck & Co., Inc., Rahway, New Jersey, USA.
Mahek GargMerck & Co., Inc., Rahway, New Jersey, USA.
Samhita ChakrabortyMerck & Co., Inc., Rahway, New Jersey, USA.
Eric M SarpongMerck & Co., Inc., Rahway, New Jersey, USA.
Claire BaiCOTA, Inc., New York, New York, USA.
Andrew J BelliCOTA, Inc., New York, New York, USA.
Laura L FernandesCOTA, Inc., New York, New York, USA.ORCID 0000-0002-5986-3885
Ching-Kun WangCOTA, Inc., New York, New York, USA.

Funding

Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
6 · The paper itself

Abstract

backgroundAlthough initial treatment of diffuse large B-cell lymphoma (DLBCL) with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) can be effective, up to 50% of patients will develop refractory or relapsed (R/R) disease. This study aimed to provide contemporary data on characteristics, treatment patterns, and outcomes for R/R-DLBCL.

methodsPatients with incident (January 2016 to March 2021) DLBCL age ≥18 years who initiated first-line (1L) therapy were identified from the COTA real-world database. Baseline characteristics, treatment patterns, and real-world outcomes, including time to next treatment (rwTTNT) and overall survival (rwOS), were assessed for the study population and by line of therapy (LOT).

resultsA total of 1347 eligible DLBCL patients were identified. Of these, 340 (25.2%) proceeded to receive 2L, of whom 141 (41.5%) proceeded to receive 3L, of whom 51 (36.2%) proceeded to receive 4L+. Most common treatments were R-CHOP in 1L (63.6%), stem cell transplant (SCT) in 2L (17.9%), polatuzumab vedotin, bendamustine, and rituximab (Pola-BR) in 3L (9.9%), and chimeric antigen receptor T-cell therapy (CAR-T) in 4L (11.8%). Treatment patterns were more variable in later LOTs. One- and 3-year rwOS from 1L initiation were 88.5% and 78.4%, respectively. Patients who received later LOTs experienced numerically lower 1- and 3-year rwOS (from 2L initiation: 62.4% and 46.4%, respectively).

conclusionsIn this real-world analysis, 25.2% of patients experienced R/R-DLBCL after 1L with poor outcomes. Given the findings of this study, there is a high unmet need for novel, safe, and effective treatment options for patients with R/R DLBCL.

Indexed as

Lymphoma, Large B-Cell, DiffuseAdolescentAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicinHumansPrednisoneRituximabTreatment OutcomeVincristineCyclophosphamideDoxorubicinPrednisoneRituximabVincristineDLBCLoutcomesrelapsed/refractorysurvivaltreatment

Identifiers

PMID38597118
PMCPMC11004909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.